Industries of Interest
BioTech | Big Data & Analytics | EdTech | Entertainment | FoodTech | Healthcare | Insurance | Renewable Energy
The first investment in the Rines Angel Fund portfolio is Platelet BioGenesis, the deal was led by the eCoast Angel Network.
Platelet BioGenesis is a pre-clinical stage biotech company that was spun out of Harvard in 2014 to produce the world's first donor-independent human platelets from pluripotent stem cells. Platelets are the ‘bandaids’ of the bloodstream, responsible for clot formation and blood vessel repair. Platelet Biogenesis has developed and patented a microfluidic bioreactor, and shown that functional platelets can be generated from human stem cell cultures at scale. Over 2 million Americans receive platelet transfusions annually that dramatically increase survival rates for cancer, transplant, and surgery patients.
Platelet BioGenesis was selected to participate in MassCONNECT (run by MassBio), was a 2014 MassChallenge Finalist, a 2016 BioSciKin business competition winner, and has received support from the Massachusetts Life Sciences Center, and the NIH.